000153793 001__ 153793
000153793 005__ 20240229123050.0
000153793 0247_ $$2doi$$a10.1093/mutage/geaa005
000153793 0247_ $$2pmid$$apmid:32083302
000153793 0247_ $$2ISSN$$a0267-8357
000153793 0247_ $$2ISSN$$a1464-3804
000153793 0247_ $$2altmetric$$aaltmetric:76525804
000153793 037__ $$aDKFZ-2020-00459
000153793 041__ $$aeng
000153793 082__ $$a610
000153793 1001_ $$aTomasova, Kristyna$$b0
000153793 245__ $$aTelomere maintenance in interplay with DNA repair in pathogenesis and treatment of colorectal cancer.
000153793 260__ $$aOxford$$bOxford Univ. Press$$c2020
000153793 3367_ $$2DRIVER$$aarticle
000153793 3367_ $$2DataCite$$aOutput Types/Journal article
000153793 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1627552018_25382$$xReview Article
000153793 3367_ $$2BibTeX$$aARTICLE
000153793 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153793 3367_ $$00$$2EndNote$$aJournal Article
000153793 500__ $$a2020 Jul 11;35(3):261-271
000153793 520__ $$aColorectal cancer (CRC) continues to be one of the leading malignancies and causes of tumour-related deaths worldwide. Both impaired DNA repair mechanisms and disrupted telomere length homeostasis represent key culprits in CRC initiation, progression and prognosis. Mechanistically, altered DNA repair results in the accumulation of mutations in the genome and, ultimately, in genomic instability. DNA repair also determines the response to chemotherapeutics in CRC treatment, suggesting its utilisation in the prediction of therapy response and individual approach to patients. Telomere attrition resulting in replicative senescence, simultaneously by-passing cell cycle checkpoints, is a hallmark of malignant transformation of the cell. Telomerase is almost ubiquitous in advanced solid cancers, including CRC, and its expression is fundamental to cell immortalisation. Therefore, there is a persistent effort to develop therapeutics, which are telomerase-specific and gentle to non-malignant tissues. However, in practice, we are still at the level of clinical trials. The current state of knowledge and the route, which the research takes, gives us a positive perspective that the problem of molecular models of telomerase activation and telomere length stabilisation will finally be solved. We summarise the current literature herein, by pointing out the crosstalk between proteins involved in DNA repair and telomere length homeostasis in relation to CRC.
000153793 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000153793 588__ $$aDataset connected to CrossRef, PubMed,
000153793 7001_ $$aKroupa, Michal$$b1
000153793 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aForsti, Asta$$b2$$udkfz
000153793 7001_ $$aVodicka, Pavel$$b3
000153793 7001_ $$aVodickova, Ludmila$$b4
000153793 773__ $$0PERI:(DE-600)1497468-x$$a10.1093/mutage/geaa005$$gp. geaa005$$n3$$p261-271$$tMutagenesis$$v35$$x1464-3804$$y2020
000153793 909CO $$ooai:inrepo02.dkfz.de:153793$$pVDB
000153793 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000153793 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000153793 9141_ $$y2020
000153793 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000153793 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153793 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153793 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153793 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000153793 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMUTAGENESIS : 2017
000153793 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153793 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153793 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153793 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000153793 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153793 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153793 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000153793 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153793 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153793 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000153793 980__ $$ajournal
000153793 980__ $$aVDB
000153793 980__ $$aI:(DE-He78)B062-20160331
000153793 980__ $$aUNRESTRICTED